Accent Capital Management »

Crispr Therapeutics shares owned by Accent Capital Management

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Accent Capital Management from 13F filings

Historical chart of Accent Capital Management investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Accent Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Accent Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $3.9k 60 64.82

More positions owned by Accent Capital Management

Apple (AAPL)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Alphabet Inc A Cl A Com (GOOG)
Vanguard Growth ETF (VUG)
Meta Platforms Inc A Cl A Com (META)
Spdr S&p 500 Etf (SPY)
Amazon (AMZN)
Vanguard S&p 500 Etf idx (VOO)
Costco Wholesale Corporation (COST)
Tesla Motors (TSLA)
JPMorgan Chase & Co. (JPM)
Eli Lilly & Co. (LLY)
Broadcom (AVGO)
Honeywell International (HON)

View all positions for Accent Capital Management

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Capital Research and Management Company - Division 3
Orbis Allan Gray
State Street Corporation
T. Rowe Price Investment Management
UBS Group
Vanguard Group
Nikko Asset Management Americas
Geode Capital Management
Susquehanna International
Sr One Capital Management
Sumitomo Mitsui Trust Holdings
Citadel Advisors
FMR

View all funds holding Crispr Therapeutics